Xpira Pharmaceuticals

Xpira Pharmaceuticals is a private psychedelic-medicine biotechnology company focused on developing proprietary therapies for eating disorders and other mental health conditions. The company has emphasized psilocybin-assisted treatment as its lead therapeutic approach, with a particular focus on anorexia nervosa. Public disclosures indicate that Xpira received U.S. FDA clearance for its first IND in 2022 and planned a Phase 2a clinical trial in anorexia nervosa. Xpira also appears to be developing formulation and delivery intellectual property around psilocybin products, including rapid-dissolution and targeted-release compositions. The company operates primarily from Toronto and has stated activities in both Canada and the Netherlands.